Form 4: CARGO Therapeutics Director Granted 25,000 Stock Options

John A. Orwin, a Director at CARGO Therapeutics, Inc. (CRGX), was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next annual meeting.

Summary

• John A. Orwin, a Director of CARGO Therapeutics, Inc. (CRGX), was granted 25,000 stock options.
• The stock options have an exercise price of $4.35 per share.
• The grant date for these options was June 18, 2025.
• The options are set to expire on June 17, 2035.
• 100% of the shares subject to the option will vest on the earlier of the one-year anniversary of June 18, 2025, or the next Annual Meeting following June 18, 2025, contingent on Mr. Orwin's continued service to the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a director is a standard practice that aligns interests and incentivizes long-term performance, indicating stability in governance and compensation practices.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages the director's continued service and commitment to the company.

Risks

• The value of the stock options is dependent on the future performance of CARGO Therapeutics' stock price; if the stock price does not exceed the exercise price of $4.35, the options may expire worthless.

Future Outlook

The document does not provide a general future outlook for the company, but the stock option grant implies an expectation of future value creation for the underlying common stock.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, used to attract and retain talent and align management incentives with shareholder interests.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of non-cash compensation in the industry, aligning the director's financial interests with the company's long-term performance.
• The vesting schedule (one year or next annual meeting) is typical for director equity grants, promoting retention and commitment.

Related Party Transactions

• The grant of stock options to John A. Orwin, a Director of CARGO Therapeutics, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the next Annual Meeting following June 18, 2025, subject to continued service.

Key Dates

Keywords

CARGO Therapeutics, CRGX, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Executive Compensation, Beneficial Ownership